The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis

Song, Haifeng; Kuang, Guanyu; Zhang, Zhenan; Ma, Binglei; Jin, Jie; Zhang, Qian

doi:10.7150/jca.26989



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(2):479-487. doi:10.7150/jca.26989 This issue Cite

Research Paper

The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis

Haifeng Song^1,2,3*, Guanyu Kuang^2,3*, Zhenan Zhang^1,2,3, Binglei Ma^1,2,3, Jie Jin^1,2,3, Qian Zhang^1,2,3✉

1. Department of Urology, Peking University First Hospital, Beijing 100034, China
2. Institute of Urology, Peking University, Beijing 100034, China
3. National Research Center for Genitourinary Oncology, Beijing 100034, China
*These authors contributed equally to this work.

Citation:

Song H, Kuang G, Zhang Z, Ma B, Jin J, Zhang Q. The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis. J Cancer 2019; 10(2):479-487. doi:10.7150/jca.26989. https://www.jcancer.org/v10p0479.htm

Other styles

Abstract

Objective: Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers.

Methods: After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and estimated hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) using a fixed-effect model.

Results: Our results indicate that pretreatment plasma fibrinogen is a prognostic factor in urological cancers (OS: HR=2.21, 95% CI=1.91-2.57, P<0.001, CSS: HR=2.67, 95% CI=2.23-3.19, P<0.001). Elevated pretreatment plasma fibrinogen is associated with poorer survival in prostate cancer (OS: HR=2.26, 95% CI=1.47-3.48, P<0.001; CSS: HR=2.42, 95% CI=1.44-4.07, P=0.001), renal cell carcinoma (OS: HR=2.13, 95% CI=1.75-2.61, P<0.001; CSS: HR=2.99, 95% CI=2.29-3.89, P<0.001) and upper tract urothelial carcinoma (OS: HR=2.34, 95% CI=1.81-3.02, P<0.001; CSS: HR=2.43, 95% CI=1.84-3.20, P<0.001). Subgroup analyses showed that plasma fibrinogen has a more negative impact on survival in Caucasian patients (OS: HR=2.52, 95% CI=1.95-3.25, P<0.001; CSS: HR=2.83, 95% CI=1.92-4.17, P<0.001) than Asian patients (OS: HR=2.07, 95% CI=1.73-2.49, P<0.001; CSS: HR=2.63, 95% CI=2.14-3.22, P<0.001). The prognostic value of fibrinogen is also consistent when stratified by different cut-off values.

Conclusions: These results show that high pretreatment plasma fibrinogen levels can predict poorer OS and CSS in patients with urological cancers.

Keywords: fibrinogen, urological cancers, prognosis, biomarker, meta-analysis

Citation styles

APA

Song, H., Kuang, G., Zhang, Z., Ma, B., Jin, J., Zhang, Q. (2019). The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis. Journal of Cancer, 10(2), 479-487. https://doi.org/10.7150/jca.26989.

ACS

Song, H.; Kuang, G.; Zhang, Z.; Ma, B.; Jin, J.; Zhang, Q. The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis. J. Cancer 2019, 10 (2), 479-487. DOI: 10.7150/jca.26989.

NLM

CSE

Song H, Kuang G, Zhang Z, Ma B, Jin J, Zhang Q. 2019. The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis. J Cancer. 10(2):479-487.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.